

(12) **UK Patent Application** (19) **GB** (11) **2 422 545** (13) **A**

(43) Date of A Publication **02.08.2006**

(21) Application No: **0601678.6**  
(22) Date of Filing: **27.01.2006**  
(30) Priority Data:  
(31) **0501719** (32) **28.01.2005** (33) **GB**

(71) Applicant(s):  
**Tristel plc**  
**(Incorporated in the United Kingdom)**  
**Unit 4c Lynx Business Park,**  
**Fordham Road, Snailwell, NEWMARKET,**  
**CB8 7NY, United Kingdom**

(72) Inventor(s):  
**Bruce Philip Green**

(74) Agent and/or Address for Service:  
**Dummett Copp**  
**25 The Square, Martlesham Heath,**  
**IPSWICH, Suffolk, IP5 3SL,**  
**United Kingdom**

(51) INT CL:  
**A61L 2/16** (2006.01) **A01N 59/00** (2006.01)  
**A61L 2/22** (2006.01) **A61L 15/00** (2006.01)  
**A61L 101/06** (2006.01)


(52) UK CL (Edition X ):  
**A5G G101**  
**A5E ES E413**  
**U1S S1307**

(56) Documents Cited:  
**GB 2410032 A** **GB 2404337 A**  
**EP 0423817 A** **EP 0175826 A**  
**EP 0081017 A** **WO 1996/010916 A**  
**JP 110229317 A**

(58) Field of Search:  
UK CL (Edition X ) **A5E, A5G, C5D**  
INT CL **A01N, A61B, A61K, C11D**  
Other: **ONLINE: WPI, EPODOC**

(54) Abstract Title: **Sterilant system**

(57) A two-part sterilant system comprises a first part comprising a first reagent in an aqueous medium having a first foam promoter dissolved therein and contained in a first dispenser whereby it may be dispensed as a first foam, and a second part comprising a second reagent in an aqueous medium having a second foam promoter dissolved therein and contained in a second dispenser whereby it may be dispensed as a second foam, wherein the first reagent and the second reagent will react to provide a sterilising composition when the first and second foam mix. Also claimed is a wound dressing system wherein the first and second reagents react to form a chlorine-dioxide containing composition when the foams mix. The system includes a woven or non-woven fabric for use as a sterile wound dressing. The claims include a system for producing a sterilising foam for use in oral hygiene applications wherein the first and second reagents react to provide a physiologically acceptable composition of chlorine-dioxide when the foams mix. A method of sterilising a surface comprising the steps of preparing first and second foams, mixing the foams and applying the foams to the surface to be sterilised is also claimed. The foams can be prepared sequentially or simultaneously and either mixed together and then applied to the surface, applied to the surface prior to mixing or mixed as they are applied.



*FIG. 1*

1/2




FIG. 1




FIG. 2

## STERILANT SYSTEM

## BACKGROUND OF THE INVENTION

## 5 1. Field of the Invention

The present invention relates to a sterilant system and method for sterilising surfaces.

## 10 2. Description of the Prior Art

Two-part sterilising solutions are used in applications where the active sterilising ingredient is unstable over time. The solution is therefore prepared *in situ* shortly before it is  
15 to be used. A particularly important sterilising agent is chlorine dioxide ( $\text{ClO}_2$ ), which may be formed from mixtures of various reagents including: chlorite and acid; chlorate, peroxide and acid; and chlorite, hypochlorite, and a suitable buffer. Chlorine dioxide has excellent sterilising and  
20 bactericidal properties, and oral ingestion in man and animals has been shown to be relatively safe.

$\text{ClO}_2$  gas is a respiratory and eye irritant so its concentration in air needs to be controlled at safe levels.  
25 The occupational exposure standard limit (OES) in the UK is set at 0.3 ppm ( $0.9 \text{ mg/m}^3$ ) as a 15 minute short term exposure limit (STEL) and at 0.1 ppm for an 8 hour time-weighted average (TWA). In the USA, OSHA, NIOSH and ACGIH all set the limit at 0.1 ppm for long-term exposure.

30

$\text{ClO}_2$  sterilising solutions have many uses, particularly in hospital and medical environments where medical equipment and apparatus such as isolation tents need to be sterilised to

reduce risks of cross-infection. The cleaning of endoscopes and other medical equipment with suitable chlorine dioxide solutions is known from earlier patents in the name of the present inventor, for example, European Patent Number 0 785 719 and United States Patent Numbers 5,696,046 and 6,007,772, the contents of which are hereby incorporated by reference.

It is not always convenient to mix up batches of solutions for use in sterilising equipment. For wiping down (rather than thoroughly cleaning inside and out) of endoscopes and probes, wipes of alcohol, general-purpose detergent, or soapy water are generally used, but these are not as effective as chlorine dioxide. It is desirable to be able readily to make up small quantities of two-component sterilising agents when desired and to be able to make such agents up in a form in which they may be readily handled for a particular application and which is compatible with OES limits.

#### SUMMARY OF THE INVENTION

20

According to an aspect of the present invention there is provided a two-part sterilant system comprising:

(a) a first part comprising a first reagent in an aqueous medium having a first foam promoter dissolved therein and contained in a first dispenser whereby it may be dispensed as a first foam; and

(b) a second part which comprises a second reagent in an aqueous medium having a second foam promoter dissolved therein and contained in a second dispenser whereby it may be dispensed as a second foam;

30

wherein the first reagent and the second reagent will react to provide a sterilising composition when the first foam is mixed with the second foam.

By dispensing each reagent in a foam the resulting sterilising composition provides good surface contact with minimal splashing. The foam may formulated to be tenacious  
5 and form-retaining so that it resists flow when applied to a vertical or sloping surface such as the plastic-walled tent of a hospital isolation unit.

Moreover, where the reagents react to produce a volatile  
10 sterilant, such as chlorine dioxide, we have found that the concentration of volatile sterilant in the air is reduced compared to a corresponding non-foamed mixture. This enables the use of higher concentrations of reagents than with a liquid system.

15 Because both reagents are dispensed in separate foams before they react together the reaction products are formed within the foam. This maximises retention of those products in the foam and on a surface to which they are applied, and  
20 minimises losses through evaporation.

The system may be used to sterilise medical apparatus and equipment, including sloping surfaces such as internal walls of isolation tents, or for sterilising hands of medical staff  
25 or patients to reduce the risk of cross-infection. The system may also be used to prepare sterilizing wound dressings, or for oral hygiene applications where reduction of bacteria within the oral cavity is desired. For this latter application the sterilising composition is preferably  $\text{ClO}_2$ ,  
30 which may be used as a mouthwash, a breath freshener, or for gum treatment. Optional flavouring, fragrancing, or colouring agents may be included in the formulations. Typically, the sterilising foam composition will be applied

via a toothbrush or other applicator, although it would be possible for a user to apply the foam directly to the oral cavity if desired.

5 The dispenser may be a conventional trigger-operated atomiser or foamer, or other manual pump foamer in which the contents are expelled manually by operation of the trigger by the user. Alternatively, the dispenser may contain a propellant to dispense the contents when operation of the trigger opens  
10 a valve, as is well known in applications such as shaving foam canisters and the like. Suitable dispensers will be well known to those skilled in the art. A foam dispenser may include a mixing chamber to facilitate mixing of the first part with air, for example as described in United States  
15 patent number 5,337,929.

In a preferred embodiment, the first dispenser and the second dispenser are connected together or provided in a common housing. Preferably, the foams are dispensed simultaneously  
20 by operation of a single trigger or other actuator. A particularly preferred dispensing apparatus is the Dual Foamer supplied by Airspray International BV. The Dual Foamer consists of two pump systems, with one single actuator operating both chambers. It is a mechanical, non-aerosol  
25 foam dispenser which dispenses the two components as foams simultaneously in a precise and fixed ratio. The foams are kept separate until the moment of application. At that point, the ingredients combine to create an instant 50:50 foam formulation. The output is 0.8 ml of liquid as foam per  
30 stroke. The manufacturer claims that the foams are dispensed without drips, spills, blotches or leaks.

The dispensers preferably have a common outlet through which

both foams are dispensed. This outlet may optionally be provided with an internal mixing chamber or a tortuous pathway which will promote mixing of the foams before they exit the common outlet.

5

The preferred sterilising agent is chlorine dioxide, which may be formed from suitable known reagents. In a preferred embodiment one reagent is a chlorite (notably sodium chlorite) and the other is an acid, preferably with a buffer.

10 Suitable acids include lactic acid, citric acid, boric acid, phosphoric acid, acetic acid, sorbic acid, ascorbic acid, hydrochloric acid or mixtures thereof. In a preferred embodiment a mixture of acids is used, notably a mixture of citric, sorbic and boric acids.

15

A particularly preferred system is as described in EP 0 785 719, with the corrosion inhibitors optionally not included, and with other additives as desired for particular applications. In addition to suitable indicators, optional  
20 additives may be selected from foam stabilisers, humectants, essential oils and fragrances. Other sterilising agents may also be employed; for example chlorine or oxygen. Chlorine may be produced by reaction between a hypochlorite such as sodium hypochlorite, and a suitable acid or buffer. Oxygen  
25 may be produced by reaction between a peroxide and a catalyst such as catalase, optionally in the presence of a buffer. For convenience hereinafter, the invention will be described with reference to chlorine dioxide as the sterilising agent.

30 Suitable foam promoters will be well known to those skilled in the art. Non-limiting examples include: sodium laureth sulphate, ammonium lauryl sulphate, cocamide DEA, cocamidopropyl betaine, sodium lauryl sarcosinate,



cocamidopropylamine oxide, monoethanolamine lauryl sulphate, cocamidopropyl hydroxysultaine, cocoyl sarcosinate. Anionic, cationic, non-ionic and amphoteric surfactants may be employed depending on the chemistry of the reagents. The  
5 foam promoters are selected to provide a stable foam structure. The foam promoter may comprise from about 0.1 to 50% by weight of each part, notably from about 1 to 10%, preferably from about 3 to 6%.

10 Suitable foam stabilisers well known to those skilled in the art may also be used, in proportions similar to those for the foam-promoters. Non-limiting examples include: alkanolamides, for example monoethanolamides and diethanolamides, amine oxides, betaines, protein hydrolysates  
15 and cellulose derivatives such as carboxymethylcellulose.

To promote foam stability it is preferred that the first foam promoter is chemically compatible with the second foam promoter; for example it is preferred that both foam  
20 promoters are anionic or that both are cationic or that both are non-ionic. In a particularly preferred embodiment, the second foam promoter is the same as the first foam promoter.

In a preferred embodiment, a humectant is included in at  
25 least one of the first and second parts, preferably in both parts. Humectants serve to reduce the rate of evaporation of components and improve product feel if direct skin contact is involved. We have found that the use of a humectant reduces the volatility of chlorine dioxide, which reduces the odour  
30 of chlorine dioxide and prolongs the life of the activated mixture. Non-limiting examples of suitable humectants include sodium lactate and polyols, for example glycerine, sorbitol, propylene glycol, diethylene glycol and ethylene

glycol. The humectant may be present in any desired amount, particularly from about 0.1 to 50% by weight, notably from about 0.5 to 10%, preferably from about 1 to 3%.

- 5 It will be understood that other solvents than water, for example ethanol or glycerol, may optionally be included in either or both of the first part and the second part providing that a sufficiently stable foam is produced.
- 10 The first and/or second part may further include a biocide to ensure that, in the event of poor mixing of the parts, a biocidal effect is still present. The first and/or second part may also include a preservative.
- 15 Equal weights of the first part and the second part may provide, when mixed, a sterilising composition having a pH of from 1.0 to 10.5, but it is preferred that the composition has a pH of from 4.5 to 6.5 as this may result in a more stable compound.
- 20 In a preferred embodiment, at least one of the first and second parts is provided with an indicator reagent that changes colour to show that sufficient mixing has taken place. Where the first part and the second part are of
- 25 different pH, the indicator may be a pH-sensitive indicator. Suitable indicators are well known to those skilled in the art, non-limiting examples including: phenol red, litmus, thymol blue, pentamethoxy red, tropeolin OO, 2,4-dinitrophenol, methyl yellow, methyl orange, bromophenol
- 30 blue, tetrabromophenol blue, alizarin sodium sulphonate,  $\alpha$ -naphthyl red, p-ethoxychrysoidine, bromocresol green, methyl red, bromocresol purple, chlorophenyl red, bromothymol blue, p-nitrophenol, azolitmin, neutral red, rosolic acid, cresol

red,  $\alpha$ -naphtholphthalein, tropeolin OOO, phenolphthalein,  $\alpha$ -  
naphtholbenzein, thymolphthalein, nile blue, alizarin yellow,  
dialzo violet, tropeolin O, nitramine, Poirrer's blue,  
trinitrobenzoic acid, and mixtures thereof. It is preferred  
5 that the indicator is selected so that both parts are  
separately colourless and the colour develops when the two  
parts are mixed.

Alternatively, or additionally, one or more fluorescent  
10 additives may be included so that the mixture fluoresces to  
indicate mixing. Non-limiting examples of suitable  
fluorescing agents include: 4-methylumbelliferone, 3,6-  
dihydroxanthone, quinine, thioflavin, 1-naphthol, harmine,  
coumarin, acridine orange, cotarmine, and mixtures thereof.

15

The indicator (colour change or fluorescent) may be included  
in either part. Preferred proportions by weight are about  
0.1 to 10%, notably about 0.5 to 2%.

20 According to another aspect of the invention there is  
provided a method of sterilising a surface, comprising the  
steps of:

- (a) preparing a quantity of a first foam from an aqueous  
medium containing a first reagent and a first foam promoter;
- 25 (b) preparing a quantity of a second foam from an aqueous  
medium containing a second reagent and a second foam  
promoter, the second reagent being capable of reacting with  
the first reagent to produce a sterilising composition;
- (c) mixing the first foam and the second foam;
- 30 (d) applying the foams to a surface to be sterilised.

It will be understood that steps (a) and (b) may be carried  
out sequentially or simultaneously and that steps (c) and (d)

may be carried sequentially in either order or simultaneously.

Preferably, equal volumes of each foam are applied.

5

In one embodiment, the sterilising composition is applied to a surface of a fabric to provide a sterilising wound dressing. In this embodiment, the sterilising composition preferably comprises ClO<sub>2</sub>.

10

Other aspects and benefits of the invention will appear in the following specification, drawings and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be further described, by way of example, with reference to the following drawings in which:

5

Figure 1 shows a sterilant system in accordance with an embodiment of the present invention; and

10

Figure 2 shows the sterilant system of Figure 1 being used to prepare a sterilising wound dressing.

DETAILED DESCRIPTION

In this specification, all parts are by weight unless otherwise indicated.

The Dual Foamer foam dispenser 2 shown in Figure 1 (from Airspray International BV) has a first dispenser chamber 4 clipped to a second dispenser chamber 6. The chambers 4, 6 are part of two small foam pump systems which dispense their contents as foams when respective piston members 14, 16 are depressed. Operation of a single actuator 8 depresses both piston members 14, 16, causing a volume of liquid (in this example, 0.8 ml) to be pumped from each chamber 4, 6 simultaneously and combined with air to form a foam. The liquid from chamber 4 is turned into a first foam and the liquid from chamber 6 is turned into a second foam. The first and second foams are dispensed via respective separate nozzle orifices 10, 12 in the actuator 8.

30

In the present example, the first dispenser chamber 4 is filled with a liquid (first part) which comprises deionised water containing 0.75% of a first reagent (sodium chlorite),

and 3.0% foam promoter (cocamidopropyl betaine).

The second dispenser chamber 6 is filled with an aqueous acid solution (second part). In this example, the acid solution  
5 comprises deionised water containing 0.5% citric acid, 0.05% sorbic acid, 0.05% boric acid, and 3.0% foam promoter (cocamidopropyl betaine). The solution also comprises 0.35% of a buffer (trisodium phosphate), 0.25% trisodium citrate, 1.0% glycerine, 0.1% benzotriazole, 0.1% sodium molybdate and  
10 0.3% sodium nitrate.

The first part and the second part are miscible as liquids and as foams to produce  $\text{ClO}_2$ . However, they are kept separate from each other until each has been turned into a  
15 foam, thereby ensuring that  $\text{ClO}_2$  is formed only within a foam and avoiding dispensing any liquid which may splash or trickle off a surface to be sterilised. We have found that the foam mixture provides effective surface sterilisation.

20 It is desirable that the  $\text{ClO}_2$  is retained on a surface that is to be sterilised, and that airborne exposure to  $\text{ClO}_2$  is kept at a safe level. Tests were carried out to measure  $\text{ClO}_2$  concentrations in air for the first and second parts when mixed as liquids and when mixed as foams. The tests used the  
25 PiezOptic Personal Gas Dosimeter System, from PiezOptic Limited, Kent TN23 6NF, UK to measure  $\text{ClO}_2$  concentrations in air. The PiezOptic system consists of small passive dosimeters (badges) which perform 5 identical tests simultaneously and which are read by a reader to provide a  
30 quantitative result. The badges are specified to monitor  $\text{ClO}_2$  concentrations in the range 0.05-0.50 ppm.

### **Experimental Method**

A test area of 60 mm x 60 mm was marked out in a butler sink and a 250 ml flask was positioned on the edge of the test  
5 area.

### **Liquids**

0.8 ml of the first part liquid was drawn into a first 1 ml  
10 syringe, and 0.8 ml of the second part liquid was drawn into another 1 ml syringe. The contents of both syringes were added to a 50 ml flask and left to react for 10 seconds. A sample of the mixture was poured onto the test area. Three PiezOptic badges were used. Badge No. 1 was positioned on  
15 the 250 ml flask at 25 mm above the mixture. Badge No. 2 was positioned 300 mm above the mixture, and Badge No. 3 was positioned 1000 mm above the mixture. The badges were left for the recommended time as per the manufacturer's instructions and ClO<sub>2</sub> air concentration results were  
20 recorded.

### **Foams**

Using the Dual Foamer, two amounts of foam solution (1.6 ml)  
25 were pumped as foam into the test area. Badges were attached and positioned, and readings of ClO<sub>2</sub> concentration in air were taken using the same positioning and timing as for the liquids.

### **30 Results**

Test results obtained from the badges for the liquids and foams are set out in Table 1.

Distance above mix.	Liquid	Foam
25 mm	>0.50 ppm	0.50 ppm
300 mm	0.13 ppm	0.05 ppm
1000 mm	0.09 ppm	0.05 ppm

Table 1

5 In each case, the concentration of ClO<sub>2</sub> in air was reduced for the foam system, which will permit higher concentrations of reagents to be used within OES limits.

Referring now to Figure 2, the foam from each nozzle is  
10 sprayed onto a surface 20 by the action of a user's finger 22 on the actuator 8. The foams mix to provide a sterilising foam composition 18 containing ClO<sub>2</sub>. In this example, the surface 20 is a surface of a fabric material, for example a gauze or bandage material, suitable for use as a wound  
15 dressing 24. The resulting wound dressing 24 may be used to dress any wound for which the use of a sterilising dressing is indicated, for example in the treatment of: burns, scalds, radiation therapy damage, cuts, abrasions, bed sores or ulcers. The wound dressing is of particular application in  
20 the dressing of leg ulcers. For wound dressing applications, antibiotics, antivirals, or other antimicrobial agents may optionally be incorporated in either or both of the first part and the second part. Suitable agents will be well known to those of ordinary skill in the art.

25

Typically, a wound to be treated will be wiped to remove any excess of exudate, and the wound dressing 24, carrying the sterilising foam composition 18, applied and held in place by suitable means, for example adhesive tape. In addition to



promoting an antimicrobial environment, it is believed that the ClO<sub>2</sub> may help to break down and aid removal of biofilms and non-viable tissue, thereby promoting wound healing.

- 5 It is to be recognized that various alterations, modifications, and/or additions may be introduced into the constructions and arrangements of parts described above without departing from the ambit of the present invention as specified in the accompanying claims.

CLAIMS

1. A two-part sterilant system comprising:

5 (a) a first part comprising a first reagent in an aqueous medium having a first foam promoter dissolved therein and contained in a first dispenser whereby it may be dispensed as a first foam; and

10 (b) a second part which comprises a second reagent in an aqueous medium having a second foam promoter dissolved therein and contained in a second dispenser whereby it may be dispensed as a second foam;

wherein the first reagent and the second reagent will react to provide a sterilising composition when the first foam is mixed with the second foam.

15

2. A sterilant system according to claim 1, wherein the first dispenser and the second dispenser are connected together or provided in a common housing.

20 3. A sterilant system according to claim 1 or claim 2, wherein the first dispenser and the second dispenser have a common actuator, the actuation of which will cause the dispensers to dispense the first and second foams simultaneously.

25

4. A sterilant system according to any preceding claim, wherein the first dispenser and the second dispenser are provided with a common outlet through which the first and second foams are dispensed together.

30

5. A sterilant system according to any preceding claim, further comprising a mixing chamber in which the first and second foam will mix together before being dispensed through

a common outlet.

6. A sterilant system according to any preceding claim,  
wherein at least one of the first part and the second part  
5 includes an indicator reagent that changes colour when the  
parts are mixed together.

7. A sterilant system according to claim 4, wherein the  
first part and the second part have a different pH and  
10 wherein the indicator reagent changes colour in response to a  
change in pH when the parts are mixed.

8. A sterilant system according to any preceding claim,  
wherein one of the first part and the second part contains  
15 sodium chlorite or sodium chlorate and the other comprises an  
acidic solution.

9. A sterilant system according to claim 8, wherein the  
acidic solution comprises a solution of citric acid, sorbic  
20 acid and boric acid.

10. A sterilant system according to any preceding claim,  
wherein the foam promoter comprises from 0.1 to 50% w/w of  
each of said first part and said second part.

25

11. A sterilant system according to claim 10, wherein said  
foam promoter comprises from 3 to 6% w/w of each of said  
first part and said second part.

30 12. A sterilant system according to any preceding claim,  
wherein at least one of the first part and the second part  
further comprises from 0.1 to 50% w/w of a humectant.

13. A sterilant system according to claim 12, wherein said humectant comprises from 1 to 3% w/w of said first part or said second part.

5 14. A sterilant system according to any preceding claim, wherein when equal weights of the first foam and the second foam are mixed they provide a sterilising composition having a pH of from 4.5 to 6.5.

10 15. A sterilant system according to any preceding claim, wherein each foam promoter is selected from the group comprising: sodium laureth sulphate, ammonium lauryl sulphate, cocamide DEA, cocamidopropyl betaine, sodium lauryl sarcosinate, cocamidopropylamine oxide, monoethanolamine  
15 lauryl sulphate, cocamidopropyl hydroxysultaine, cocoyl sarcosinate.

16. A sterilant system according to any preceding claim wherein the first foam promoter is the same chemical or  
20 composition as the second foam promoter.

17. A sterilant system according to any preceding claim, wherein at least one of the first part and the second part further comprises a foam stabiliser selected from the group  
25 comprising: alkanolamides, amine oxides, betaines, protein hydrolysates, and cellulose derivatives.

18. A sterilant system according to any preceding claim, wherein the first reagent and the second reagent will react  
30 to form chlorine dioxide when the first foam is mixed with the second foam.

19. A sterilant system according to any preceding claim,

further comprising a woven or non-woven fabric for receiving the first and second foams, suitable for use as a wound dressing.

5 20. A wound dressing system comprising:

(a) a first part comprising a first reagent in an aqueous medium having a first foam promoter dissolved therein and contained in a first dispenser whereby it may be dispensed as a first foam; and

10 (b) a second part which comprises a second reagent in an aqueous medium having a second foam promoter dissolved therein and contained in a second dispenser whereby it may be dispensed as a second foam;

wherein the first reagent and the second reagent will  
15 react to provide a chlorine dioxide-containing sterilising composition when the first foam is mixed with the second foam; and

(c) a woven or non-woven fabric for receiving the sterilising composition, for use as a sterile wound dressing.

20

21. A system for producing a sterilising foam for use in oral hygiene applications, the system comprising:

(a) a first part comprising a first reagent in an aqueous medium having a first foam promoter dissolved therein and

25 contained in a first dispenser whereby it may be dispensed as a first foam; and

(b) a second part which comprises a second reagent in an aqueous medium having a second foam promoter dissolved

30 therein and contained in a second dispenser whereby it may be dispensed as a second foam;

wherein the first reagent and the second reagent will react to provide a physiologically acceptable concentration of chlorine dioxide when the first foam is mixed with the

second foam.

22. A method of sterilising a surface, comprising the steps of:

- 5 (a) preparing a quantity of a first foam from an aqueous medium containing a first reagent and a first foam promoter;
- (b) preparing a quantity of a second foam from an aqueous medium containing a second reagent and a second foam promoter, the second reagent being capable of reacting with
- 10 the first reagent to produce a sterilising composition;
- (c) mixing the first foam and the second foam; and
- (d) applying the foams to a surface to be sterilised;
- wherein steps (a) and (b) are carried out sequentially or simultaneously and wherein steps (c) and (d) are carried
- 15 out sequentially in either order or simultaneously.

23. A method according to claim 22, wherein the foams are applied together through a common outlet.

20 24. A method according to claim 22 or claim 23, wherein the foams are applied simultaneously by actuation of a common actuator.

25 25. A method according to any of claims 23-24, wherein the surface is the surface of a woven or non-woven fabric material suitable for use as a wound dressing.

26. A method of sterilising a surface substantially as herein described with reference to the drawings.

30

27. A two-part sterilant system substantially as herein described with reference to the drawings.

28. A wound dressing substantially as herein described with reference to Figure 2 of the drawings.

## Amendments to the claims have been filed as follows

### CLAIMS

1. A two-part sterilant system comprising:

(a) a first part comprising a first reagent in an aqueous  
5 medium having a first foam promoter dissolved therein and  
contained in a first dispenser whereby it may be dispensed as  
a first foam; and

(b) a second part which comprises a second reagent in an  
aqueous medium having a second foam promoter dissolved  
10 therein and contained in a second dispenser whereby it may be  
dispensed as a second foam;

wherein the first reagent and the second reagent will  
react to provide a sterilising composition when the first  
foam is mixed with the second foam.

15

2. A sterilant system according to claim 1, wherein the  
first dispenser and the second dispenser are connected  
together or provided in a common housing.

20 3. A sterilant system according to claim 1 or claim 2,  
wherein the first dispenser and the second dispenser have a  
common actuator, the actuation of which will cause the  
dispensers to dispense the first and second foams  
simultaneously.

25

4. A sterilant system according to any preceding claim,  
wherein the first dispenser and the second dispenser are  
provided with a common outlet through which the first and  
second foams are dispensed together.

30

5. A sterilant system according to any preceding claim,  
further comprising a mixing chamber in which the first and  
second foam will mix together before being dispensed through



a common outlet.

6. A sterilant system according to any preceding claim,  
wherein at least one of the first part and the second part  
5 includes an indicator reagent that changes colour when the  
parts are mixed together.

7. A sterilant system according to claim 4, wherein the  
first part and the second part have a different pH and  
10 wherein the indicator reagent changes colour in response to a  
change in pH when the parts are mixed.

8. A sterilant system according to any preceding claim,  
wherein one of the first part and the second part contains  
15 sodium chlorite or sodium chlorate and the other comprises an  
acidic solution.

9. A sterilant system according to claim 8, wherein the  
acidic solution comprises a solution of citric acid, sorbic  
20 acid and boric acid.

10. A sterilant system according to any preceding claim,  
wherein the foam promoter comprises from 0.1 to 50% w/w of  
each of said first part and said second part.

25

11. A sterilant system according to claim 10, wherein said  
foam promoter comprises from 3 to 6% w/w of each of said  
first part and said second part.

30 12. A sterilant system according to any preceding claim,  
wherein at least one of the first part and the second part  
further comprises from 0.1 to 50% w/w of a humectant.

13. A sterilant system according to claim 12, wherein said humectant comprises from 1 to 3% w/w of said first part or said second part.
- 5 14. A sterilant system according to any preceding claim, wherein when equal weights of the first foam and the second foam are mixed they provide a sterilising composition having a pH of from 4.5 to 6.5.
- 10 15. A sterilant system according to any preceding claim, wherein each foam promoter is selected from the group comprising: sodium laureth sulphate, ammonium lauryl sulphate, cocamide DEA, cocamidopropyl betaine, sodium lauryl sarcosinate, cocamidopropylamine oxide, monoethanolamine  
15 lauryl sulphate, cocamidopropyl hydroxysultaine, cocoyl sarcosinate.
16. A sterilant system according to any preceding claim wherein the first foam promoter is the same chemical or  
20 composition as the second foam promoter.
17. A sterilant system according to any preceding claim, wherein at least one of the first part and the second part further comprises a foam stabiliser selected from the group  
25 comprising: alkanolamides, amine oxides, betaines, protein hydrolysates, and cellulose derivatives.
18. A sterilant system according to any preceding claim, wherein the first reagent and the second reagent will react  
30 to form chlorine dioxide when the first foam is mixed with the second foam.
19. A sterilant system according to any preceding claim,

further comprising a woven or non-woven fabric for receiving the first and second foams, suitable for use as a wound dressing.

5 20. A wound dressing system comprising:

(a) a first part comprising a first reagent in an aqueous medium having a first foam promoter dissolved therein and contained in a first dispenser whereby it may be dispensed as a first foam; and

10 (b) a second part which comprises a second reagent in an aqueous medium having a second foam promoter dissolved therein and contained in a second dispenser whereby it may be dispensed as a second foam;

wherein the first reagent and the second reagent will  
15 react to provide a sterilising composition when the first foam is mixed with the second foam; and

(c) a woven or non-woven fabric for receiving the sterilising composition, for use as a sterile wound dressing.

20 21. A wound dressing system according to claim 20, wherein the sterilising composition comprises chlorine dioxide.

22. A system for producing a sterilising foam for use in oral hygiene applications, the system comprising:

25 (a) a first part comprising a first reagent in an aqueous medium having a first foam promoter dissolved therein and contained in a first dispenser whereby it may be dispensed as a first foam; and

(b) a second part which comprises a second reagent in an  
30 aqueous medium having a second foam promoter dissolved therein and contained in a second dispenser whereby it may be dispensed as a second foam;

wherein the first reagent and the second reagent will

react to provide a physiologically acceptable concentration of a sterilising composition when the first foam is mixed with the second foam.

5 23. A system according to claim 22, wherein the sterilising composition comprises chlorine dioxide.

24. A method of sterilising a surface, comprising the steps of:

- 10 (a) preparing a quantity of a first foam from an aqueous medium containing a first reagent and a first foam promoter;  
(b) preparing a quantity of a second foam from an aqueous medium containing a second reagent and a second foam promoter, the second reagent being capable of reacting with  
15 the first reagent to produce a sterilising composition;  
(c) mixing the first foam and the second foam; and  
(d) applying the foams to a surface to be sterilised;  
wherein steps (a) and (b) are carried out sequentially or simultaneously and wherein steps (c) and (d) are carried  
20 out sequentially in either order or simultaneously.

25. A method according to claim 24, wherein the foams are applied together through a common outlet.

25 26. A method according to claim 24 or claim 25, wherein the foams are applied simultaneously by actuation of a common actuator.

27. A method according to any of claims 24-26, wherein the  
30 surface is the surface of a woven or non-woven fabric material suitable for use as a wound dressing.

28. A method of sterilising a surface substantially as





For Innovation

**Application No:** GB0601678.6

**Examiner:** Mr Chris Archer

**Claims searched:** 1-28

**Date of search:** 25 April 2006

**Patents Act 1977: Search Report under Section 17**

**Documents considered to be relevant:**

Category	Relevant to claims	Identity of document and passage or figure of particular relevance
P	-	GB 2410032 A (RECKITT BENCKISER) see whole document.
A	-	GB 2404337 A (GREEN) see whole document.
A	-	EP 0081017 A (ALCIDE) see page 4 line 18 to page 5 line 15.
A	-	WO 96/10916 A (GREEN) see whole document.
A	-	EP 0423817 A (BRISTOL-MYERS SQUIBB) see claim 1.
A	-	JP 11229317 A (BUSINESS PLAN) see WPI AN: 1999-522560 [44] attached.
A	-	EP 0175826 A (RIO LINDA) see the examples.

**Categories:**

X Document indicating lack of novelty or inventive step	A Document indicating technological background and/or state of the art.
Y Document indicating lack of inventive step if combined with one or more other documents of same category	P Document published on or after the declared priority date but before the filing date of this invention
& Member of the same patent family	E Patent document published on or after, but with priority date earlier than, the filing date of this application.

**Field of Search:**

Search of GB, EP, WO & US patent documents classified in the following areas of the UKC<sup>X</sup> :

A5E; A5G; C5D

Worldwide search of patent documents classified in the following areas of the IPC

A01N; A61B; A61K; C11D

The following online and other databases have been used in the preparation of this search report



For Innovation

28

WPI, EPODOC